Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study

Annamaria Ferrero, Daniela Dompè, Nicoletta Ravarino, Angela Ramella, Luca Fuso, Furio Maggiorotto, Elisa Tripodi, Paolo Zola

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: The role of molecular markers in ovarian cancer is still a matter of debate. Angiogenesis is a necessary condition for tumor growth. Hypoxia induces angiogenesis, and cyclooxygenase-2 (COX-2), p53 and HER2 are involved in cancer proliferation and angiogenesis regulation. The aims of this study were to evaluate the relationship between intratumoral microvessel density (IMD) and the expression of molecular markers that affect angiogenesis (COX-2, p53 and HER2) in advanced epithelial ovarian cancer (EOC), to analyze their prognostic and predictive value and their association with clinicopathological features, such as serum hemoglobin level at diagnosis (Hb). Methods: Immunohistochemical staining with CD34 (for IMD), COX-2, p53 and HER2 antibodies was performed in 113 patients with advanced EOC who had undergone primary surgery. Clinicopathological data were collected and statistical analyses were performed. Results: Neither IMD, COX-2 nor HER2 had any predictive or prognostic value in EOC. A relationship that approached statistical significance was found between p53 expression and a complete response to treatment (p = 0.05). p53 expression and tumor grade were inversely associated (p = 0.012). Hb <12 g/dl had predictive value (p = 0.02). Conclusions: In our series IMD, COX-2 and HER2 had neither prognostic nor predictive value in advanced EOC. p53 and Hb may be predictive factors. The results and clinical usefulness of immunohistochemistry are controversial. Further evaluations are required to determine whether the serum levels of molecular markers correlate with the results of immunohistochemical assays and whether they offer any prognostic and/or predictive value. Targeted therapy remains the ultimate goal of these studies.

Original languageEnglish
Pages (from-to)301-307
Number of pages7
JournalGynecologic Oncology
Volume123
Issue number2
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Cyclooxygenase 2
Microvessels
Retrospective Studies
Neoplasms
Serum
Ovarian Neoplasms
Hemoglobins
Immunohistochemistry
Ovarian epithelial cancer
Staining and Labeling
Antibodies
Therapeutics
Growth

Keywords

  • Angiogenesis
  • Epitelian ovarian cancer
  • Molecular markers

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Angiogenesis and molecular markers in advanced epithelial ovarian cancer : A retrospective study. / Ferrero, Annamaria; Dompè, Daniela; Ravarino, Nicoletta; Ramella, Angela; Fuso, Luca; Maggiorotto, Furio; Tripodi, Elisa; Zola, Paolo.

In: Gynecologic Oncology, Vol. 123, No. 2, 11.2011, p. 301-307.

Research output: Contribution to journalArticle

Ferrero, A, Dompè, D, Ravarino, N, Ramella, A, Fuso, L, Maggiorotto, F, Tripodi, E & Zola, P 2011, 'Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study', Gynecologic Oncology, vol. 123, no. 2, pp. 301-307. https://doi.org/10.1016/j.ygyno.2011.07.026
Ferrero, Annamaria ; Dompè, Daniela ; Ravarino, Nicoletta ; Ramella, Angela ; Fuso, Luca ; Maggiorotto, Furio ; Tripodi, Elisa ; Zola, Paolo. / Angiogenesis and molecular markers in advanced epithelial ovarian cancer : A retrospective study. In: Gynecologic Oncology. 2011 ; Vol. 123, No. 2. pp. 301-307.
@article{47952a4320dd4cb0969173843118dd44,
title = "Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study",
abstract = "Objective: The role of molecular markers in ovarian cancer is still a matter of debate. Angiogenesis is a necessary condition for tumor growth. Hypoxia induces angiogenesis, and cyclooxygenase-2 (COX-2), p53 and HER2 are involved in cancer proliferation and angiogenesis regulation. The aims of this study were to evaluate the relationship between intratumoral microvessel density (IMD) and the expression of molecular markers that affect angiogenesis (COX-2, p53 and HER2) in advanced epithelial ovarian cancer (EOC), to analyze their prognostic and predictive value and their association with clinicopathological features, such as serum hemoglobin level at diagnosis (Hb). Methods: Immunohistochemical staining with CD34 (for IMD), COX-2, p53 and HER2 antibodies was performed in 113 patients with advanced EOC who had undergone primary surgery. Clinicopathological data were collected and statistical analyses were performed. Results: Neither IMD, COX-2 nor HER2 had any predictive or prognostic value in EOC. A relationship that approached statistical significance was found between p53 expression and a complete response to treatment (p = 0.05). p53 expression and tumor grade were inversely associated (p = 0.012). Hb <12 g/dl had predictive value (p = 0.02). Conclusions: In our series IMD, COX-2 and HER2 had neither prognostic nor predictive value in advanced EOC. p53 and Hb may be predictive factors. The results and clinical usefulness of immunohistochemistry are controversial. Further evaluations are required to determine whether the serum levels of molecular markers correlate with the results of immunohistochemical assays and whether they offer any prognostic and/or predictive value. Targeted therapy remains the ultimate goal of these studies.",
keywords = "Angiogenesis, Epitelian ovarian cancer, Molecular markers",
author = "Annamaria Ferrero and Daniela Domp{\`e} and Nicoletta Ravarino and Angela Ramella and Luca Fuso and Furio Maggiorotto and Elisa Tripodi and Paolo Zola",
year = "2011",
month = "11",
doi = "10.1016/j.ygyno.2011.07.026",
language = "English",
volume = "123",
pages = "301--307",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Angiogenesis and molecular markers in advanced epithelial ovarian cancer

T2 - A retrospective study

AU - Ferrero, Annamaria

AU - Dompè, Daniela

AU - Ravarino, Nicoletta

AU - Ramella, Angela

AU - Fuso, Luca

AU - Maggiorotto, Furio

AU - Tripodi, Elisa

AU - Zola, Paolo

PY - 2011/11

Y1 - 2011/11

N2 - Objective: The role of molecular markers in ovarian cancer is still a matter of debate. Angiogenesis is a necessary condition for tumor growth. Hypoxia induces angiogenesis, and cyclooxygenase-2 (COX-2), p53 and HER2 are involved in cancer proliferation and angiogenesis regulation. The aims of this study were to evaluate the relationship between intratumoral microvessel density (IMD) and the expression of molecular markers that affect angiogenesis (COX-2, p53 and HER2) in advanced epithelial ovarian cancer (EOC), to analyze their prognostic and predictive value and their association with clinicopathological features, such as serum hemoglobin level at diagnosis (Hb). Methods: Immunohistochemical staining with CD34 (for IMD), COX-2, p53 and HER2 antibodies was performed in 113 patients with advanced EOC who had undergone primary surgery. Clinicopathological data were collected and statistical analyses were performed. Results: Neither IMD, COX-2 nor HER2 had any predictive or prognostic value in EOC. A relationship that approached statistical significance was found between p53 expression and a complete response to treatment (p = 0.05). p53 expression and tumor grade were inversely associated (p = 0.012). Hb <12 g/dl had predictive value (p = 0.02). Conclusions: In our series IMD, COX-2 and HER2 had neither prognostic nor predictive value in advanced EOC. p53 and Hb may be predictive factors. The results and clinical usefulness of immunohistochemistry are controversial. Further evaluations are required to determine whether the serum levels of molecular markers correlate with the results of immunohistochemical assays and whether they offer any prognostic and/or predictive value. Targeted therapy remains the ultimate goal of these studies.

AB - Objective: The role of molecular markers in ovarian cancer is still a matter of debate. Angiogenesis is a necessary condition for tumor growth. Hypoxia induces angiogenesis, and cyclooxygenase-2 (COX-2), p53 and HER2 are involved in cancer proliferation and angiogenesis regulation. The aims of this study were to evaluate the relationship between intratumoral microvessel density (IMD) and the expression of molecular markers that affect angiogenesis (COX-2, p53 and HER2) in advanced epithelial ovarian cancer (EOC), to analyze their prognostic and predictive value and their association with clinicopathological features, such as serum hemoglobin level at diagnosis (Hb). Methods: Immunohistochemical staining with CD34 (for IMD), COX-2, p53 and HER2 antibodies was performed in 113 patients with advanced EOC who had undergone primary surgery. Clinicopathological data were collected and statistical analyses were performed. Results: Neither IMD, COX-2 nor HER2 had any predictive or prognostic value in EOC. A relationship that approached statistical significance was found between p53 expression and a complete response to treatment (p = 0.05). p53 expression and tumor grade were inversely associated (p = 0.012). Hb <12 g/dl had predictive value (p = 0.02). Conclusions: In our series IMD, COX-2 and HER2 had neither prognostic nor predictive value in advanced EOC. p53 and Hb may be predictive factors. The results and clinical usefulness of immunohistochemistry are controversial. Further evaluations are required to determine whether the serum levels of molecular markers correlate with the results of immunohistochemical assays and whether they offer any prognostic and/or predictive value. Targeted therapy remains the ultimate goal of these studies.

KW - Angiogenesis

KW - Epitelian ovarian cancer

KW - Molecular markers

UR - http://www.scopus.com/inward/record.url?scp=80054725663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054725663&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.07.026

DO - 10.1016/j.ygyno.2011.07.026

M3 - Article

C2 - 21862119

AN - SCOPUS:80054725663

VL - 123

SP - 301

EP - 307

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -